These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 31352053)
41. Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures. Blakney AK; Krogstad EA; Jiang YH; Woodrow KA Int J Nanomedicine; 2014; 9():2967-78. PubMed ID: 24971008 [TBL] [Abstract][Full Text] [Related]
42. Using Emoji Stickers to Understand End-User Opinions of the Dapivirine Vaginal Ring for HIV Prevention. Katz AWK; Mansoor LE; Tsidya M; Mathebula F; Singh D; Siva S; Akello C; Chitowa TH; Garcia M; Soto-Torres L; Montgomery ET AIDS Behav; 2021 Dec; 25(12):3955-3966. PubMed ID: 34180041 [TBL] [Abstract][Full Text] [Related]
43. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring. Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404 [TBL] [Abstract][Full Text] [Related]
44. Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial. Palanee-Phillips T; Roberts ST; Reddy K; Govender V; Naidoo L; Siva S; Gafoor Z; Pather A; Matovu F; Hlahla K; Makanani B; Nair G; Schwartz K; Torjesen K; Brown E; Soto-Torres L; Baeten J; Montgomery ET J Acquir Immune Defic Syndr; 2018 Dec; 79(5):580-589. PubMed ID: 30239426 [TBL] [Abstract][Full Text] [Related]
45. Ring-ing in the Future: Participant and Male Partner Perspectives Regarding Future Use of the Dapivirine Vaginal Ring for HIV Prevention. Reddy K; Mathebula F; Katz A; Luecke E; Tenza S; Palanee-Phillips T; Garcia M; Mansoor LE; Naidoo S; Morar N; Chitukuta M; Tsidya M; Montgomery ET; AIDS Behav; 2022 Jun; 26(6):1923-1932. PubMed ID: 35064389 [TBL] [Abstract][Full Text] [Related]
46. A dynamic mechanical method for determining the silicone elastomer solubility of drugs and pharmaceutical excipients in silicone intravaginal drug delivery rings. Malcolm RK; McCullagh S; Woolfson AD; Catney M; Tallon P Biomaterials; 2002 Sep; 23(17):3589-94. PubMed ID: 12109683 [TBL] [Abstract][Full Text] [Related]
47. Development and Characterization of a Vaginal Film Containing Dapivirine, a Non- nucleoside Reverse Transcriptase Inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. Akil A; Parniak MA; Dezzuitti CS; Moncla BJ; Cost MR; Li M; Rohan LC Drug Deliv Transl Res; 2011 Jun; 1(3):209-222. PubMed ID: 22708075 [TBL] [Abstract][Full Text] [Related]
48. Porosity of maxillofacial silicone elastomers and microleakage pattern of the commercially pure Ti-silicone elastomer interface after hydrothermal cycling. Artopoulou II; Chambers MS; Eliades G J Prosthet Dent; 2016 Dec; 116(6):937-942. PubMed ID: 27460319 [TBL] [Abstract][Full Text] [Related]
49. Dapivirine Vaginal Ring for HIV-1 Prevention. Seidman D; Weber S; Aaron E N Engl J Med; 2017 Mar; 376(10):995. PubMed ID: 28273024 [No Abstract] [Full Text] [Related]
50. Dapivirine Vaginal Ring for HIV-1 Prevention. Baeten JM; Brown ER; Hillier SL N Engl J Med; 2017 Mar; 376(10):995-6. PubMed ID: 28273023 [No Abstract] [Full Text] [Related]
51. Dapivirine Vaginal Ring for HIV-1 Prevention. Winceslaus SJ N Engl J Med; 2017 Mar; 376(10):994-5. PubMed ID: 28276229 [No Abstract] [Full Text] [Related]
52. Persistence of antimicrobial activity through sustained release of triclosan from pegylated silicone elastomers. McBride MC; Karl Malcolm R; David Woolfson A; Gorman SP Biomaterials; 2009 Dec; 30(35):6739-47. PubMed ID: 19765822 [TBL] [Abstract][Full Text] [Related]
53. Post-use assay of vaginal rings (VRs) as a potential measure of clinical trial adherence. Spence P; Nel A; van Niekerk N; Derrick T; Wilder S; Devlin B J Pharm Biomed Anal; 2016 Jun; 125():94-100. PubMed ID: 27016673 [TBL] [Abstract][Full Text] [Related]
55. Rational Design of a Multipurpose Bioadhesive Vaginal Film for Co-Delivery of Dapivirine and Levonorgestrel. Li J; Regev G; Patel SK; Patton D; Sweeney Y; Graebing P; Grab S; Wang L; Sant V; Rohan LC Pharmaceutics; 2019 Dec; 12(1):. PubMed ID: 31861267 [TBL] [Abstract][Full Text] [Related]
56. Estradiol-progesterone interaction during the preparation of vaginal rings. Saleh SI; Khidr SH; Ahmed SM; Jackanicz TM; Nash HA J Pharm Sci; 2003 Feb; 92(2):258-65. PubMed ID: 12532375 [TBL] [Abstract][Full Text] [Related]
57. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel. Landgren BM; Johannisson E; Xing S; Aedo AR; Diczfalusy E Contraception; 1985 Dec; 32(6):581-601. PubMed ID: 3937664 [TBL] [Abstract][Full Text] [Related]
58. [Current status of contraceptive vaginal rings]. Elstein M; Jackson R; Hickling D; Assendorp R Contracept Fertil Sex (Paris); 1992 Jan; 20(1):15-9. PubMed ID: 12343624 [TBL] [Abstract][Full Text] [Related]
59. [Menstrual blood loss and body iron stores: comparative study between a Multiload-375 IUD and a levonorgestrel vaginal ring]. Souza JP; Andrade AT; Pizarro E Bol Cent Biol Reprod; 1991; 10(1):26-32. PubMed ID: 12318141 [TBL] [Abstract][Full Text] [Related]
60. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles. Alvarez-Sanchez F; Brache V; Jackanicz T; Faundes A Contraception; 1992 Oct; 46(4):387-98. PubMed ID: 1486777 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]